Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 25Parkinson Disease 4, Autosomal Dominant Lewy Body 18Multiple Myeloma 13Neoplasms 12Leukemia, Myeloid, Acute 12Ovarian Neoplasms 10Neoplasm Metastasis 10Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 9Prostatic Neoplasms 8Colorectal Neoplasms 8Melanoma 7Lymphoma, Non-Hodgkin 7Leukemia 7Stomach Neoplasms 6Recurrence 6Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Carcinoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 5Adenocarcinoma 5Purpura, Thrombocytopenic, Idiopathic 4Myelodysplastic Syndromes 4Lymphoma, Follicular 4Liver Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Pathologic Processes × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡